Medical specialists from Netherlands tagged as investigators in clinical trials studying Melanoma

Total 45 results

Alexander van Akkooi, MD, PhD
Seen in:
- Amsterdam, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Trials:
- NCT01942603 (Principal Investigator)
Conditions:
- Cutaneous Melanoma
Anneriet Dassen
Seen in:
- Enschede, Medisch Spectrum Twente
Trials:
- NCT05569707 (Principal Investigator)
Conditions:
- Melanoma (Skin)
Arwen H Pieterse, PhD
Seen in:
- Zuid-Holland, Leiden, Leiden University Medical Center
Trials:
- NCT05377957 (Sub-Investigator)
Conditions:
- Uveal Melanoma
Astrid van der Veldt, MD
Seen in:
- Rotterdam, Erasmus MC
Trials:
- NCT05155254 (Principal Investigator)
Conditions:
- Metastatic Melanoma;
- Unresectable Melanoma
Barbara Leeuwen
Seen in:
- Groningen, University Medical Centre Groningen
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Christian Blank, M.D.
Seen in:
- Amsterdam, The Netherlands Cancer Institute
Trials:
- NCT05155254 (Principal Investigator)
Conditions:
- Metastatic Melanoma;
- Unresectable Melanoma
Christian U Blank, Prof MD PhD
Seen in:
- Amsterdam, The Netherlands Cancer Institute
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts
Coen RN Rasch, MD PhD
Seen in:
- Zuid-Holland, Leiden, Leiden University Medical Center
Trials:
- NCT05377957 (Principal Investigator)
Conditions:
- Uveal Melanoma
Cor Lamers, PhD
Seen in:
- Rotterdam, Erasmus Medical Center
Trials:
- NCT04729543 (Sub-Investigator)
Conditions:
Daniëlle de Leeuw
Seen in:
- Hengelo, Ziekenhuisgroep Twente (ZGT)
Trials:
- NCT05569707 (Principal Investigator)
Conditions:
- Melanoma (Skin)
Dirk Grunhagen
Seen in:
- Rotterdam, Erasmus MC Cancer Institute - location Daniel den Hoed
- Rotterdam, Erasmus Mc Cancer Institute
Trials:
- NCT01942603 (Principal Investigator)
- NCT03685890 (Principal Investigator)
Conditions:
Djura Piersma, MD, PhD
Seen in:
- Enschede, Medisch Spectrum Twente
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts
Dominique van Uden, MD
Seen in:
- Gelderland, Zutphen, Gelre Hospital
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
E. G.E. de Vries, MD, PhD
Seen in:
- Groningen, University Medical Center Groningen
Trials:
- NCT04193956 (Principal Investigator)
Conditions:
- Melanoma;
- Non-Small Cell Lung Cancer
Ellen Kapiteijn, Dr.
Seen in:
- Leiden, LUMC
- Leiden, Leiden University Medical Center
- Leiden, Leids Universitair Medisch Centrum
- Zuid-Holland, Leiden, Leiden University Medical Center
Trials:
- NCT03638375 (Principal Investigator)
- NCT05155254 (Principal Investigator)
- NCT05013099 (Principal Investigator)
- NCT04283890 (Principal Investigator)
- NCT02968303 (Principal Investigator)
Conditions:
Ellen Kapitejin, MD
Seen in:
- Leiden, Leiden University Medical Center
Trials:
- NCT04879017 (Principal Investigator)
Conditions:
- Metastatic Uveal Melanoma
Fons van den Eertwegh, MD
Seen in:
- Amsterdam, AMC Amsterdam, locatie VUMC
- Amsterdam, Vrije Universiteit Medisch Centrum
Trials:
- NCT05155254 (Principal Investigator)
- NCT02968303 (Principal Investigator)
Conditions:
Franchette van den Berkmortel, MD, PhD
Seen in:
- Heerlen, Zuyderland Medisch Centrum Heerlen
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts
Frank Speetjens, MD, PhD
Seen in:
- Zuid-Holland, Leiden, Leiden University Medical Center
Trials:
- NCT04283890 (Sub-Investigator)
Conditions:
- Uveal Melanoma, Metastatic
Gré PM Luyten, MD PhD
Seen in:
- Zuid-Holland, Leiden, Leiden University Medical Center
Trials:
- NCT05377957 (Principal Investigator)
Conditions:
- Uveal Melanoma
Gwen Diepenhorst
Seen in:
- Flevoland, Almere, Flevo Hospital
Trials:
- NCT03860883 (Principal Investigator)
Conditions:
- Cutaneous Melanoma, Stage II
Hilde Jalving, MD, PhD
Seen in:
- Groningen, Universitair Medisch Centrum Groningen
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts
J. B.A.G. Haanen, MD, PhD
Seen in:
- Amsterdam, NKI-AVL
Trials:
- NCT04193956 (Principal Investigator)
Conditions:
- Melanoma;
- Non-Small Cell Lung Cancer
Johannes WB de Groot, MD PhD
Seen in:
- Zwolle, Isala
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts
John B.A.G Haanen, Dr.
Seen in:
- Amsterdam, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Trials:
- NCT03235245 (Principal Investigator)
Conditions:
- Stage IV Melanoma;
- Unresectable Stage III Melanoma
K.Suijkerbuijk@umcutrecht.nl Suijkerbuijk, MD, PhD
Seen in:
- Utrecht, UMC Utrecht
Trials:
- NCT02968303 (Principal Investigator)
Conditions:
- Melanoma, Malignant, of Soft Parts

Clinical Trials on Melanoma

H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States

Medical specialists from Netherlands tagged as investigators in clinical trials studying Melanoma

Clinical Trials on Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations